Report Highlights
The report provides a detailed description of autoimmune responses and possible ways that drug development can augment immune responses so as to improve antitumor activity and reduce off target effect.
This report will assess the latest developments in the IL-2 research and development and explore the novel strategies companies are adopting to augment immune response and avoid off target effects in a wide range of conditions including, metastatic melanoma (MM), renal cell carcinoma (RCC), urothelial cancers (US) relapse remitting multiple sclerosis (RRMS), Type 1 diabetes (T1D), as a prophylaxis post-transplant and allergic conditions.
What's coming: There are more than 200 studies underway evaluating IL-2 based therapies either as a monotherapy or in combination. The key products and companies that we believe are worth watching in this space are summarized.
Report Includes
- An introduction to interleukin-2 (IL-2) and identification of its applications
- Insights into the latest trends and technologies in the IL-2 research and development
- Discussion of strategies adopted by IL-2 developers for the successful treatment of cancer and information on NKTR-214, a Nektar Therapeutics product
- Review of recent VC investment in this zone highlighted by Syncona and Novartis Venture Fund recent CHF35m investment in Anaveon AG, a new Swiss Biotech company spun out from the University of Zuirich which is developing a novel oncologic monoclonal antibody that boosts IL-2 but has an improved side-effect profile
- Detailed description of autoimmune responses and possible ways to augment immune responses so as to improve antitumor activity and reduce off target effect
- An understanding of various conditions which may develop as an off-target effects in the cancer treatment such as metastatic melanoma (MM), renal cell carcinoma (RCC), urothelial cancers (US) relapse remitting multiple sclerosis (RRMS), and Type 1 diabetes (T1D)
Analyst Credentials
Dr. Cheryl Lee Barton has more than 10 years’ practical pharmaceutical research experience with a leading pharmaceutical company and has served as a Pan-European Pharmaceutical analyst with a European bank. Dr. C.L. Barton Ltd. aims to provide independent, tailor-made, pharmaceutical thematic research to investment houses. Research reports combine independent scientific analysis with patients- and prescription-based models to forecast the potential sales growth of key developmental drugs and to isolate the key drivers within the pharmaceutical sector. For further information, visit www.pharmavision.co.uk.
Related Reports
Tumor Infiltrating Lymphocytes: A New Frontier in Cancer Immunotherapy
This report will assess the latest developments that are taking place with regard to the current research and development environment of TILs and explore the novel strategies companies are adopting to identify and enhance TIL selection, biosynthesis and delivery in a wide range of metastatic cancers including, melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors.
Colorectal Cancer Therapeutics: Global Markets
The global colorectal cancer therapeutics market should reach $18.5 billion by 2023 from $13.7 billion in 2018 at a compound annual growth rate (CAGR) of 6.1% for the period 2018 to 2023.
Brain Tumor Therapeutics: Global Markets to 2023
The global market for brain tumor therapeutics should grow from $1.1 billion in 2018 to reach $2.0 billion by 2023 at a compound annual growth rate (CAGR) of 12.9% for the period of 2018-2023.
Lung Cancer Therapeutics: Global Markets
The global market for lung cancer therapeutics should grow from $17.9 billion in 2018 to $26.3 billion by 2023, increasing at a compound annual growth rate (CAGR) of 8.0% from 2018 to 2023.
Recent Reports
Drugs and Diagnostics for Hematological Disorders: Global Markets
The global market for drugs and diagnostics for hematological disorders is expected to grow from $131.2 billion in 2024 and is projected to reach $189.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.6% during the forecast period of 2024 to 2029.
Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets
The global market for gastrointestinal (GI) therapeutics and diagnostics is expected to grow from $86.0 billion in 2023 and projected to reach $122.5 billion by the end of 2028, at a compound annual growth rate (CAGR) of 7.3% during the forecast period of 2023 to 2028.
Global Markets and Technologies for Advanced Drug Delivery Systems
The global market for advanced drug delivery systems is expected to increase from $262.6 billion in 2023 to $359.1 billion by the end of 2028, with a compound annual growth rate (CAGR) of 6.5% during the forecast period of 2023-2028.
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets
The global market for prostate cancer care is expected to grow from $37.9 billion in 2023 to $56.4 billion by the end of 2028, at a compound annual growth rate (CAGR) of 8.3% from 2023 through 2028.
Chagas Disease: American trypanosomiasis Market
The report provides detailed coverage of the Chagas Disease market. It analyzes the market trends and epidemiology of CD, and the regional markets of CD. It highlights the current market for CD and gives a detailed analysis of the competitive environment. The report depicts the complete scenario of Chagas Disease, types of parasites that cause human African trypanosomiasis (HAT) and its presence in various regions of the world.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More